Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
To evaluate the efficacy, safety, recurrence site, recurrence pattern and resistance mechanism of 160mg furmonertinib as first-line therapy in advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR classical mutations(19Del or L858R).
Advanced or Metastatic Non-small Cell Lung Cancer
DRUG: Furmonertinib
Progression Freae Survival (PFS), The time from the first dose of the study drugs to the progression of the disease or death for any reason according to RECIST 1.1 by investigator, Approximately 24 months after the first patient begin study treatment
Objective Response Rate (ORR), Rate of subjects whose tumors are assessed as complete response(CR) or partial response(PR) according to RECIST 1.1., Approximately 12 weeks after the last patient begin study treatment|Disease Control Rate (DCR), Rate of subjects whose tumors are assessed as CR, PR or stable disease (SD) according to RECIST 1.1, Approximately 12 weeks after the last patient begin study treatment|Overall survival (OS), The time from the first dose of the study drugs to the death for any reason according to RECIST 1.1, Approximately 24 months after the last patient begin study treatment|Central Nervous System Objective Response Rate (CNS ORR), Rate of subjects whose CNS tumors are assessed as complete response(CR) or partial response(PR) according to RECIST 1.1, Approximately 12 weeks after the last patient begin study treatment|Central Nervous System Disease Control Rate (CNS DCR), Rate of subjects whose CNS tumors are assessed as CR, PR or stable disease (SD) according to RECIST 1.1, Approximately 12 weeks after the last patient begin study treatment|Central Nervous System Progression Free Survival (CNS PFS), The time from the first dose of the study drugs to the progression of the CNS disease or death for any reason according to RECIST 1.1, Approximately 24 months after the first patient begin study treatment|Adverse Events (AEs), The number of patients with adverse events and the severity according to CTCAE v5.0, From the start of study drug to 28 days after the last dose of study drug
To evaluate the PFS, ORR, DCR, OS, CNS ORR CNS DCR, CNS PFS, safety, recurrence site, recurrence pattern and resistance mechanism of 160mg furmonertinib as first-line therapy in advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR classical mutations(19Del or L858R).